These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3657909)

  • 1. In vitro sensitivity of environmental isolates of pathogenic dematiaceous fungi to azole compounds and a phenylpropyl-morpholine derivative.
    Okeke CN; Gugnani HC
    Mycopathologia; 1987 Sep; 99(3):175-81. PubMed ID: 3657909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimycotic susceptibility testing of agents of black grain eumycetoma.
    Venugopal PV; Venugopal TV; Ramakrishna ES; Ilavarasi S
    J Med Vet Mycol; 1993; 31(2):161-4. PubMed ID: 8389847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents.
    Odds FC; Webster CE; Abbott AB
    J Antimicrob Chemother; 1984 Aug; 14(2):105-14. PubMed ID: 6094418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro comparison of the antifungal activities of R34,000, miconazole and amphotericin B.
    Dixon DM; Wagner GE; Shadomy S; Shadomy HJ
    Chemotherapy; 1978; 24(6):364-7. PubMed ID: 699677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility studies with oxiconazole (Ro 13-8996).
    Gebhart RJ; Espinel-Ingroff A; Shadomy S
    Chemotherapy; 1984; 30(4):244-7. PubMed ID: 6086246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disk diffusion susceptibility testing of dermatophytes with imidazoles.
    Venugopal PV; Venugopal TV
    Indian J Pathol Microbiol; 1995 Oct; 38(4):369-74. PubMed ID: 9726146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro studies of a new imidazole antimycotic, bifonazole, in comparison with clotrimazole and miconazole.
    Yamaguchi H; Hiratani T; Plempel M
    Arzneimittelforschung; 1983; 33(4):546-51. PubMed ID: 6683531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro inhibitory activities of 2 new orally absorbable imidazole derivatives: BAY n 7133 and BAY 1 9139.
    Fromtling RA; Yu HP; Shadomy S
    Sabouraudia; 1983 Sep; 21(3):179-84. PubMed ID: 6314564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro studies of a new oral azole antimycotic, BAY N 7133.
    Yamaguchi H; Hiratani T; Plempel M
    J Antimicrob Chemother; 1983 Feb; 11(2):135-49. PubMed ID: 6300015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies with R 51,211 (itraconazole).
    Espinel-Ingroff A; Shadomy S; Gebhart RJ
    Antimicrob Agents Chemother; 1984 Jul; 26(1):5-9. PubMed ID: 6089654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative action of 8 azole derivatives against Candida albicans: fungistatic action and cytologic study by scanning electron microscopy].
    Mallie M; Jouvert S; Bastide M; Montes B; Lebecq JC; Bastide JM
    Pathol Biol (Paris); 1988 May; 36(5):575-80. PubMed ID: 3043361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiological characteristics of environmental isolates of pathogenic dematiaceous fungi.
    Gugnani HC; Okeke CN
    Mycoses; 1989 Feb; 32(2):78-83. PubMed ID: 2710157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A replica plating technique for in vitro study of susceptibility of Candida albicans to miconazole, econazole and ketoconazole: some data for standardization.
    Sanchez-Sousa A; Gomez-Criado C; Jimenez ML; Fernandez-Jorge A; Baquero F
    Ann Inst Pasteur Microbiol (1985); 1985; 136A(3):371-80. PubMed ID: 3901880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp.
    Hernández Molina JM; Llosá J; Martinez Brocal A; Ventosa A
    Mycopathologia; 1992 Apr; 118(1):15-21. PubMed ID: 1406898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antifungal activity of sertaconazole.
    Drouhet E; Dupont B
    Arzneimittelforschung; 1992 May; 42(5A):705-10. PubMed ID: 1627187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of bifonazole (BAY H 4502) with clotrimazole in vitro.
    Shadomy S; Dixon DM; May R
    Sabouraudia; 1982 Dec; 20(4):313-23. PubMed ID: 7157107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antifungal activity of luliconazole against nondermatophytic moulds.
    Maeda J; Koga H; Yuasa K; Neki D; Nanjoh Y; Inagaki K; Reangchainam S; Kampirapap K; Makimura K; Harada K; Tsuboi R
    Med Mycol; 2020 Jul; 58(5):703-706. PubMed ID: 31758690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of filamentous fungi from mycotic keratitis to azole drugs.
    Shobana CS; Mythili A; Homa M; Galgóczy L; Priya R; Babu Singh YR; Panneerselvam K; Vágvölgyi C; Kredics L; Narendran V; Manikandan P
    J Mycol Med; 2015 Mar; 25(1):44-9. PubMed ID: 25541256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of Malassezia furfur against azole compounds.
    Schmidt A; Rühl-Hörster B
    Mycoses; 1996; 39(7-8):309-12. PubMed ID: 9009652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002.
    Shadomy S; Espinel-Ingroff A; Kerkering TM
    Sabouraudia; 1984; 22(1):7-15. PubMed ID: 6322364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.